Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluguard vs Vaxigrip quadrivalent seasonal influenza vaccine immunogenicity and safety study
IRCT20240409061458N1Phase 3Completed
- Sponsor
- Nivad Pharmed Salamat
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of favipiravir in influenza (2 arms), sponsored by Nivad Pharmed Salamat. Primary endpoints: Immunogenicity and Safety. Started Sep 2024; status: completed.
02
Drugs
favipiravir
03
Conditions
influenza
Beyond the preview
Go deeper on IRCT20240409061458N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240409061458N1.